Drug Policy 101: Biosimilars

  • January 1, 2019

Biologics — drugs derived from living organisms that are used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and some cancers — are the fastest growing component of prescription drug spending.

Drug Policy 101: FDA Risk Evaluation and Mitigation Strategy (REMS)

  • November 1, 2018

Over the past couple of decades, pharmaceutical innovation has provided many new treatments for diseases that previously had limited therapeutic options. However, some of these specialty treatments have well documented side effects (known as adverse events) that must be carefully…

Drug Policy 101: Pay-for-Delay

  • April 1, 2018

The term “pay-for-delay” refers to a tactic used by brand name drug manufacturers to delay a potential competitor from bringing a generic drug alternative to market. Usually in the form of a cash payment, pay-for-delay transactions result from a patent…